N2OFF: MitoCareX Identifies Hit Compounds and Targets Preclinical Candidate Nomination
N2OFF, Inc. (NITO)
Company Research
Source: GlobeNewswire
Neve Yarak, Israel, Nov. 18, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF”), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, following the completion of its acquisition of MitoCareX Bio Ltd., today shared an update from the Chief Executive Officer of MitoCareX, Dr. Alon Silberman, including a shareholder letter that outlines the company’s strategic direction, near-term milestones, and development plans within the rapidly expanding precision oncology market. Dear Shareholders, It is with great enthusiasm that we share with you the progress and vision of MitoCareX Bio Ltd., a pioneering biotechnology company powered by MITOLINE™, MitoCareX’s proprietary algorithm designed to enable reliable 3D modeling of mitochondrial transport proteins. MITOLINE™ drives the company’s drug discovery process from concept to validation, supporting the development of novel therapies for hard-to-treat cancers through a uniquely mitoc
Show less
Read more
Impact Snapshot
Event Time:
NITO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NITO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NITO alerts
High impacting N2OFF, Inc. news events
Weekly update
A roundup of the hottest topics
NITO
News
- N2OFF Completed Merger with Cancer Drug Discovery Company Targeting Tough-to-Treat Pancreatic and Lung CancersGlobeNewswire
- N2OFF Announces Closing of Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung CancerGlobeNewswire
- N2OFF (NASDAQ:NITO) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- N2OFF regains compliance with Nasdaq minimum bid price requirement [Seeking Alpha]Seeking Alpha
- N2OFF Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewswire
NITO
Sec Filings
- 11/12/25 - Form 8-K/A
- 11/3/25 - Form DEF
- 10/28/25 - Form SCHEDULE
- NITO's page on the SEC website